Actavis has received two separate approvals from the US Food & Drug Administration to market Bupropion Hydrochloride extended-release tablets (SR).
Bupropion Hydrochloride extended-release tablets are the generic equivalent of Wellbutrin and are used in the treatment of major depressive disorders. Annual sales of brand and generic Wellbutrin were US$ 498 million for 2007, according to IMS Health data.
Bupropion Hydrochloride extended-release tablets can also be used as an aid to stop smoking – the generic equivalent of Zyban. Annual sales of brand and generic Zyban were US$ 12 million for 2007 according to IMS Health data.
“These approvals further enhance our strength in the area of modified release products and provide valuable options to our customers and patients,” said Terry Fullem, US Vice President of Marketing and Portfolio.
Distribution of Bupropion Hydrochloride extended-release tablets will commence immediately.
Actavis is a leading generic pharmaceuticals company which specialises in the development, manufacture and sale of generic pharmaceuticals. Based in Iceland, the company has operations in 40 countries and 11,000 employees.
Visit the Actavis website for more information on Bupropion Hydrochloride.
October 17, 2025, Oslo, Norway - Canadian Seafood Treasures, the new international brand created by…
London, UK - 16.10.2026 — As artificial intelligence tools become embedded in university life, a…
London, UK - 16.10.2025 — Cyberseer, one of Darktrace’s earliest Managed Security Service Provider (MSSP) partners…
Reykjavik, Iceland, 07.10.2025 - The Icelandic growth agency Ceedr, in collaboration with TBWA in Copenhagen,…
London, UK – October 3, 2025 — Santa has spoken — and this year, he’s…
Zürich, Switzerland – October 3, 2025 — In an era where visibility equals vulnerability, a…